Open AccessCASC 2: An emerging tumour‐suppressing long noncoding RNA in human cancers and melanoma
Author(s) -
Yu Xin,
Zheng Heyi,
Tse Gary,
Zhang Lin,
Wu William Ka Kei
Publication year - 2018
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12506
Subject(s) - rna , long non coding rna , wnt signaling pathway , cancer research , cancer , melanoma , non coding rna , biomarker , biology , rna binding protein , gene , genetics
Abstract Deregulation of long noncoding RNA s (lnc RNA s) has been implicated in tumourigenesis. Cancer Susceptibility Candidate 2 ( CASC 2) is a lnc RNA downregulated in multiple cancer types, including endometrial, lung, gastric and colorectal cancers. CASC 2 functions as a tumour‐suppressive lnc RNA though multiple mechanisms, such as sequestration of oncogenic micro RNA s and repression of Wnt/β‐catenin signalling. Pertinent to clinical practice, the use of CASC 2 as a prognostic marker has been demonstrated in sporadic studies. These findings suggested that CASC 2 might play an important role in human cancers and melanoma. More efforts are warranted to examine the function role of CASC 2 in other cancer types. Further validation is also needed to promote its development to be a clinically utilizable prognostic biomarker.